Ironwood Pharma (IRWD) Misses Q3 EPS by 5c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Join SI Premium – FREE
Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of $0.02, $0.05 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $91.59 million versus the consensus estimate of $90.9 million.
GUIDANCE:
Ironwood Pharma sees FY2024 revenue of $350-375 million, versus the consensus of $357.1 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
- Netflix gains after Ackman endorsement and AI feature launch
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
